The actual device was discarded by the involved facility.Therefore, the investigation was based on the evaluation of the user facility information and a retention sample from the same manufacturing date as the reported device.Visual inspection revealed no anomalies in the appearance.Bovine blood was circulated in the sample, while the pressure loss at the cr filter housed inside the reservoir was determined.The obtained values were confirmed to meet manufacturing specifications.No anomalies which could lead to clot formation were noted.Bovine blood was circulated in the sample for 6 hours.During this circulation, no obstruction occurred in the circulation and there were no visible clot formation found inside.The cr filter was disassembled and rinsed with saline solution.Subsequent visual inspection of the cr filter and defoamer set inside the cr filter found no clot formation on those components.The cr filter and defoamer were rinsed with hypochlorous acid solution so as to remove the blood cell components adhering on them.Subsequent electron microscopic inspection of those components did not reveal any anomalies which could lead blood to clot.A review of the device history record and the product release decision control sheet of the involved product code/lot # combination was conducted with no relevant findings.A search of the complaint file found no other report with the involved product code/lot# combination.There is no evidence that this event was related to a device defect or malfunction.The investigation result verified that the retention sample had no anomalies which could lead to the reported clotting.Although the exact cause of the reported event cannot be definitively determined based on the available information, many clinical variables could have lead to the reported issue.The device labeling does address the potential for such an event in the instructions-for-use (ifu) with statements such as the following: "do not reduce heparin during circulation.Otherwise, blood clotting might occur.Adequate heparinization of the blood is required to prevent it from clotting in the system." (b)(4).All available information has been placed on file in quality assurance at the manufacturing facility for appropriate tracking, trending and follow-up.Actual device was discarded.
|